



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

August 4, 2021

Dror Ben-Asher  
Chief Executive Officer  
RedHill Biopharma Ltd.  
21 Ha'arba'a Street  
Tel Aviv 6473921  
Israel

**Re: RedHill Biopharma Ltd.  
Registration Statement on Form F-3  
Filed July 29, 2021  
File No. 333-258259**

Dear Mr. Ben-Asher:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jordan Nimitz at 202-551-6001 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Perry Wildes